Previous 10 | Next 10 |
Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive b rings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the dis...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will be released after the market closes ...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reports an...
Aerie Pharmaceuticals (NASDAQ:AERI) appoints Raj Kannan as CEO and a director, effective December 20, 2021. Raj Kannan has over 25 years of experience leading and developing companies, most recently he served as the CEO and President of Chiasma. Recently, the company inked...
Aerie Pharmaceuticals (NASDAQ:AERI) has named Raj Kannan, a former executive at Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY), as the company’s new Chief Executive Officer effective Dec. 20. Raj, a 25-year veteran in leadership, will also join Aerie’s board as a director. Before joinin...
An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Ex...
Aerie Pharmaceuticals (NASDAQ:AERI) and Santen (OTC:SNPHF) have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expand...
Agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an exclusive development an...
Aerie Pharmaceuticals’ (AERI) Q3 2021 Earnings Conference Call November 04, 2021 05:00 PM ET Company Participants John LaRocca - General Counsel Benjamin McGraw - Interim Executive Chairman of the Board of Directors Thomas Mitro - President and Chief Operating Officer David Hollander -...
Image source: The Motley Fool. Aerie Pharmaceuticals, inc (NASDAQ: AERI) Q3 2021 Earnings Call Nov 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aerie Pharmaceuticals, inc (AERI) Q3 2021 Earnings Call Transcrip...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...